Tirzepatide provides consistent heart failure (HF) treatment benefits regardless of sex, according to a secondary analysis of the SUMMIT trial published July 10 in JACC: Heart Failure. While women and men present with distinct physiological differences—including varying levels of adiposity and heart structure—the drug showed similar effectiveness in reducing cardiovascular death and improving quality of life across both groups.
Clinical Findings from the SUMMIT Trial
The analysis, led by Barry A. Borlaug, evaluated 731 patients with heart failure with preserved ejection fraction (HFpEF) and a body mass index (BMI) of at least 30 kg/m². Participants were randomized to receive either tirzepatide or a placebo. Researchers tracked primary outcomes, including the time to cardiovascular death or worsening heart failure, alongside changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score over 52 weeks.
Did you know?
In the study, women showed a stronger link between weight loss and improved heart failure symptoms compared to their male counterparts, suggesting that body composition plays a distinct role in how women experience treatment success.
Physiological Differences Between Men and Women
The study highlighted significant biological disparities at baseline. Women in the trial typically presented with higher BMI, greater waist-to-height ratios, and more severe symptoms. Conversely, men exhibited more pronounced left ventricular remodeling and higher levels of paracardiac fat. Researchers also identified that a higher waist-to-height ratio was linked to poorer kidney function in women, a correlation not present in the male cohort.
Treatment Efficacy Across Sexes
Despite these baseline differences, tirzepatide’s impact remained remarkably uniform. The hazard ratio for cardiovascular death or worsening heart failure was 0.66 for women and 0.61 for men. Improvements in the KCCQ-CSS scores were also comparable, with an 8.1-point improvement for women and a 5.5-point improvement for men after adjusting for the placebo effect. Six-minute walking distances showed similar trends, with a 16-meter improvement for women and 15 meters for men.
Pro Tip: Understanding Body Composition in HFpEF
Clinicians should note that while treatment outcomes are similar, the underlying drivers of heart failure—such as inflammation and exercise dysfunction—may be more heavily tied to excess body fat in women.
Frequently Asked Questions
- Does tirzepatide work differently for men and women with heart failure?
No. The SUMMIT trial analysis found that tirzepatide’s effectiveness in reducing cardiovascular death and improving quality of life was consistent across both sexes. - What physiological differences were noted between the sexes?
Women tended to have higher BMI and symptom severity, while men showed more significant left ventricular remodeling and paracardiac fat deposition. - How did weight loss affect treatment outcomes?
Among those treated, women showed a stronger statistical association between reductions in body weight and improvements in heart failure symptom scores compared to men.
Are you a healthcare provider or patient interested in the latest cardiovascular research? Subscribe to our newsletter for monthly updates on clinical trial results and emerging heart failure therapies.
Related reading